Related Experiment Video
Updated: May 9, 2025

Subcostal Specimen Removal in Completely Portal Robotic Lobectomy
Published on: April 19, 2024
Patient-Reported Symptom Burden Associated with Treatment Modality for Malignant Bowel Obstruction
Sarah B Bateni1,2, Calvin H L Law1,3, Ashlie Nadler1
1Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Objective:
To compare patient-reported outcomes after hospitalization for malignant bowel obstruction (MBO) treated with surgical, procedural, or medical intervention.
Background:
The optimal palliative treatment for MBO is unclear due to the paucity of research examining patient-reported outcomes, including symptom relief, after MBO treatment.
Methods:
We performed a population-level analysis of individuals with incurable gastric, pancreatic, and colorectal cancer and hospitalized with a MBO from 2010-2019 with prospectively collected Edmonton Symptom Assessment System (ESAS) scores in Ontario, Canada. Mixed linear models were used to compare scores by treatment from -1-6 months from MBO admission.
Results:
Of 1,749 MBO patients, 55.3% underwent surgery, 38.5% underwent medical care, and 6.2% underwent a procedure. Moderate-to-severe symptom scores (≥4) were highest for tiredness, lack of well-being, and lack of appetite the month prior to (46.6%, 45.8%, & 42.9%) and after MBO (53.4%, 51.9%, & 42.9%). There was a ≥10% decrease in percentage of patients reporting moderate-to-severe ESAS scores for pain, tiredness, and lack of appetite and well-being over the 6-month period. Except for lack of appetite and pain, there were no differences in scores over time based on treatment (P>0.05). Those who underwent surgery reported a greater decrease in symptom scores for lack of appetite and pain over time compared to those who underwent medical care (P≤0.05).
Conclusions:
Patients hospitalized with MBO reported improvements in symptoms over time, with surgical patients reporting slightly greater symptom relief over time for appetite and pain. These data suggest a potential palliative benefit associated with surgery in select patients.
More Related Videos
07:14A Quantitative Sensory Testing Paradigm to Obtain Measures of Pain Processing in Patients Undergoing Breast Cancer Surgery
Published on: January 18, 2018
06:28E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Assessment of the Rectum and Anus
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome III: Medical and Nursing Management
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...